Dupilumab exposure and atopic-dermatitis response
A coupled subcutaneous PK and indirect-response model linking dupilumab exposure to EASI and IGA response dynamics while accounting for patient and disease covariates.
- Therapeutic
- Dupilumab
- Target
- IL4R, CD124
- Disease
- Moderate-to-severe atopic dermatitis
Biological model
A coupled subcutaneous PK and indirect-response model linking dupilumab exposure to EASI and IGA response dynamics while accounting for patient and disease covariates.
Intervention
Dupilumab
Biological focus
IL4R, CD124
Context
Moderate-to-severe atopic dermatitis
Model details
A coupled subcutaneous PK and indirect-response model linking dupilumab exposure to EASI and IGA response dynamics while accounting for patient and disease covariates.
Modeled states
- auc mg day lmg*day/L
Modeled dynamic state for auc mg day l.
- central mgmg
Modeled dynamic state for central mg.
- easi response tukeydimensionless
Modeled dynamic state for easi response tukey.
- elapsed dayday
Modeled dynamic state for elapsed day.
- iga responsedimensionless
Modeled dynamic state for iga response.
- peripheral mgmg
Modeled dynamic state for peripheral mg.
- sc depot mgmg
Modeled dynamic state for sc depot mg.
- transit1 mgmg
Modeled dynamic state for transit1 mg.
- transit2 mgmg
Modeled dynamic state for transit2 mg.
- transit3 mgmg
Modeled dynamic state for transit3 mg.
Key readouts
- Central dupilumab concentrationunknown
Model-derived readout for central dupilumab concentration.
- EASI responsedimensionless
Model-derived readout for easi response.
- IGA responsedimensionless
Model-derived readout for iga response.
- Cumulative dupilumab exposuremg*day/L
Model-derived readout for cumulative dupilumab exposure.
- central mgmg
Model-derived readout for central mg.
Explore this model
Choose a starting point to view its result. Adjust key model inputs when you want to explore a different outcome.
Adult severe AD 600 mg load, 300 mg every 2 weeks
How do dupilumab exposure and patient covariates shape the onset and depth of EASI and IGA response? Explore this intervention regimen through Central dupilumab concentration, EASI response, IGA response, Cumulative dupilumab exposure. This is a mechanistic product exploration, not a paper-result reproduction.
Questions to explore
- How do dupilumab exposure and patient covariates shape the onset and depth of EASI and IGA response?
Starting result
This result reflects the starting settings. Run your changes to update it.
Model inputs
Five scientist-facing controls at most.
Compare a parameter
How does one model input change the response?
How do dupilumab exposure and patient covariates shape the onset and depth of EASI and IGA response?
body weight kg
Model parameter controlling body weight kg.
Exploratory range around the default value.
5 evenly spaced values in kg. Other model inputs and the simulation window stay fixed.
Interpret with care
- Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.
- Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario.
Review the server-confirmed fixed price before starting the comparison.
Comparative response
End-of-window response across the selected parameter values.
Choose an exploratory range around the default, review the fixed price, and run the comparison.
Scientific reference
Supporting publication
Integrated Exposure–Response of Dupilumab in Children, Adolescents, and Adults With Atopic Dermatitis Using Categorical and Continuous Efficacy Assessments: A Population AnalysisPharmaceutical Research
